C-LECTA
23.9.2022 09:36:37 CEST | Business Wire | Press release
OFB Projektentwicklung has started the first construction phase of the “BioSquare Leipzig” on a partial area of around 11,600 m² of the construction site 6a on the street “Alte Messe.” The symbolic groundbreaking ceremony on September 22, 2022, took place in the presence of Thomas Dienberg (Mayor for Urban Development and Construction of the City of Leipzig), Dr. Marc Struhalla (CEO of c-LEcta GmbH) and Dr. Christoph Wiechmann (Office Manager for Leipzig at OFB Projektentwicklung). The ceremony marks the start of a modern campus for biotechnology and the life sciences that comprises several buildings. The excavation of around 35,000 m³ of soil is scheduled to be completed by mid-November this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005032/en/
From left to right: Dr. Marc Struhalla (CEO of c-LEcta GmbH), Dr. Christoph Wiechmann (OFB Leipzig) and Thomas Dienberg (Mayor for Urban Development and Construction of the City of Leipzig).
As early as February 2022, a facade competition was held for the project with five architectural firms and a jury consisting of politicians, architects, scientists, the tenant c-LEcta and OFB. The Leipzig-based firm KLM Architekten und Ingenieure GmbH has now been commissioned as building planner for the first construction phase with the facade design.
Above ground, the first construction phase consists of two independent buildings with a total of around 18,500 m² of rental space. Five floors are planned for Building A, which will be used by the biotechnology company c-LEcta GmbH in the future and will have around 10,500 m² of above-ground rental space.
c-LEcta has been located at the “Alte Messe” site since the company was founded in 2004, and moved into its headquarters in the BioCube in 2012. The company has changed significantly since then: What began as a university spin-off with five employees has now evolved into a leading global player in industrial biotechnology. In 2021, c-LEcta worked with over 400 customers from more than 40 countries in the food and pharmaceutical industries, and once again significantly increased its sales compared to the previous year. Along with this, the number of employees has also developed rapidly over the years. Since 2018 alone, the number has doubled to 120 employees. Further growth in the workforce is also planned in the years ahead, so there will not be enough space available for the office and laboratory space in the current building.
The neighboring Building B in the direction of Prager Strasse comprises seven stories and thus offers a view over the old trade fair grounds after their completion. The slight offset of the second building will create a forecourt that provides an inviting access to building B with a good quality stay. Furthermore, a shared underground parking garage with around 110 parking spaces is being built.
Construction work on c-Lecta’s new corporate headquarters is scheduled for completion in the first half of 2025. In the second building of the first construction phase, another 8,000 m² of rental space is being created. With floor heights of four meters and modern construction grids, both buildings offer maximum flexibility in terms of use, so that both office space and laboratory space can be realized.
“The BioSquare project development underscores Leipzig’s importance as an innovation center for biotechnology and the life sciences. We want to keep innovative companies in these future industries at the location and attract new ones. Of course, we are particularly pleased that c-LEcta, a Leipzig success story, is moving into the first construction phase,” said the mayor and alderman for Urban Development and Construction of the City of Leipzig, Thomas Dienberg.
“The groundbreaking ceremony for our new headquarters in Leipzig is obviously a very special moment. In 2025, we will move into a high-tech building here with state-of-the-art workplaces and laboratories. This will not only secure sufficient space for further development in the long term, but at the same time provide a state-of-the-art design concept for our employees. Collaboration, concentrated work and regeneration go hand in hand. We are pleased to be able to continue our history at our home location,” emphasized Dr. Marc Struhalla, CEO of the tenant c-LEcta.
Dr. Christoph Wiechmann, head of OFB’s Leipzig office, is also quite pleased: “It is great to see that the excavators are now turning and the realization phase of BioSquare has begun. The ‘Alte Messe’ has made a name for itself as a location for innovative companies. On our campus, we offer research institutions and technology companies completely new development opportunities and perfect framework conditions.”
The project site is located within sight of the well-known double M of the Leipzig Mustermesse. The neighboring S-Bahn station “Völkerschlachtdenkmal” as well as several streetcar and bus lines offer very good public transport connections. The freeway ring road can also be reached in less than five minutes. Several innovative research institutions and companies such as the Fraunhofer IZI, the Max Planck Institute, Bio-City or the German Center for Integrative Biodiversity Research (iDiv) have settled at the “Alte Messe” location in recent years.
OFB: WE CONTINUE TO DEVELOP.
OFB Projektentwicklung GmbH has been in the real estate business for over 60 years. And is still as committed as on the first day. As a subsidiary of Landesbank Hessen-Thüringen and part of the Helaba Immobiliengruppe, high-quality and sustainable large-scale real estate is our focus. Project development, project management and real estate management are our passion.
At our headquarters in Frankfurt/Main and in our branches in Berlin, Erfurt, Munich, Düsseldorf and Leipzig, around 140 employees realize successful real estate projects throughout Germany. In doing so, we want to work harder than others – and therefore take the interaction of economic, ecological and social components into account as early as the planning stage of our projects. The goal: to develop our projects further, and ourselves as well.
About c-LEcta
c-LEcta is a global biotechnology company specializing in the development, production and distribution of enzyme products. The company uses world-class enzyme engineering and production technologies to provide its partners in the food and pharmaceutical industries with superior biotechnological solutions for innovative industrial applications. Product development is based on the proprietary enzyme technology platform ENESYZ® and is carried out both in-house and in close cooperation with industry partners worldwide. c-LEcta supplies its products to more than 400 customers in over 40 countries. c-LEcta currently employs more than 120 people at its headquarters in Leipzig.
c-LEcta is part of the Kerry Group. Kerry is the world’s leading taste and nutrition partner for the food, beverage and pharmaceutical markets. The company employs 22,000 people across over 150 locations and uses its broad range of ingredient solutions to innovate with its customers and create great tasting products, with improved nutrition and functionality, while ensuring a better impact for the planet.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005032/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
